Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options

Romy Strauß, Thomas Rose, Shaun M. Flint, Jens Klotsche, Thomas Häupl, Markus Peck-Radosavljevic, Taketoshi Yoshida, Chieko Kyogoku, Alexandra Flechsig, Amy M. Becker, Kathryn H. Dao, Andreas Radbruch, Gerd Rüdiger Burmester, Paul A. Lyons, Laurie S. Davis, Falk Hiepe, Andreas Grützkau, Robert Biesen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Abstract: Interferon alpha and its surrogates, including IP-10 and SIGLEC1, paralleled changes of disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon signature (WBIFNS)—the current standard for type I IFN assessment in SLE—does not correlate with SLE disease activity in individual patients over time. The underlying causes for this apparent contradiction have not been convincingly demonstrated. Using a multicenter dataset of gene expression data from leukocyte subsets in SLE, we identify distinctive subset-specific contributions to the WBIFNS. In a subsequent analysis, the effects of type I interferon on cellular blood composition in patients with SLE and hepatitis B were also studied over time. We found that type I interferon mediates significant alterations in whole blood composition, including a neutropenia and relative lymphocytosis. Given different effects of type 1 interferon on different leukocyte subsets, these shifts confound measurement of a type 1 interferon signature in whole blood. To minimize and overcome these limitations of the WBIFNS, we suggest to measure IFN-induced transcripts or proteins in a specific leukocyte subset to improve clinical impact of interferon biomarkers. Key messages: Myeloid cells contribute more to the WBIFNS in SLE than their lymphocytic counterpart.Very similar leukocyte subsets reveal distinctive IFN signatures.IFN alpha mixes up composition of blood and leads to a preferential neutropenia, yielding relative lymphocytosis.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalJournal of Molecular Medicine
DOIs
StateAccepted/In press - Mar 29 2017

Fingerprint

Interferon Type I
Virus Diseases
Autoimmunity
Leukocytes
Biomarkers
Systemic Lupus Erythematosus
Interferons
Lymphocytosis
Neutropenia
Myeloid Cells
Hepatitis B
Interferon-alpha
Gene Expression

Keywords

  • Biomarker
  • Disease activity
  • Systemic lupus erythematosus
  • Type I interferon

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Type I interferon as a biomarker in autoimmunity and viral infection : a leukocyte subset-specific analysis unveils hidden diagnostic options. / Strauß, Romy; Rose, Thomas; Flint, Shaun M.; Klotsche, Jens; Häupl, Thomas; Peck-Radosavljevic, Markus; Yoshida, Taketoshi; Kyogoku, Chieko; Flechsig, Alexandra; Becker, Amy M.; Dao, Kathryn H.; Radbruch, Andreas; Burmester, Gerd Rüdiger; Lyons, Paul A.; Davis, Laurie S.; Hiepe, Falk; Grützkau, Andreas; Biesen, Robert.

In: Journal of Molecular Medicine, 29.03.2017, p. 1-13.

Research output: Contribution to journalArticle

Strauß, R, Rose, T, Flint, SM, Klotsche, J, Häupl, T, Peck-Radosavljevic, M, Yoshida, T, Kyogoku, C, Flechsig, A, Becker, AM, Dao, KH, Radbruch, A, Burmester, GR, Lyons, PA, Davis, LS, Hiepe, F, Grützkau, A & Biesen, R 2017, 'Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options', Journal of Molecular Medicine, pp. 1-13. https://doi.org/10.1007/s00109-017-1515-7
Strauß, Romy ; Rose, Thomas ; Flint, Shaun M. ; Klotsche, Jens ; Häupl, Thomas ; Peck-Radosavljevic, Markus ; Yoshida, Taketoshi ; Kyogoku, Chieko ; Flechsig, Alexandra ; Becker, Amy M. ; Dao, Kathryn H. ; Radbruch, Andreas ; Burmester, Gerd Rüdiger ; Lyons, Paul A. ; Davis, Laurie S. ; Hiepe, Falk ; Grützkau, Andreas ; Biesen, Robert. / Type I interferon as a biomarker in autoimmunity and viral infection : a leukocyte subset-specific analysis unveils hidden diagnostic options. In: Journal of Molecular Medicine. 2017 ; pp. 1-13.
@article{d17984ad89164cf8bde16d8806b3f37c,
title = "Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options",
abstract = "Abstract: Interferon alpha and its surrogates, including IP-10 and SIGLEC1, paralleled changes of disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon signature (WBIFNS)—the current standard for type I IFN assessment in SLE—does not correlate with SLE disease activity in individual patients over time. The underlying causes for this apparent contradiction have not been convincingly demonstrated. Using a multicenter dataset of gene expression data from leukocyte subsets in SLE, we identify distinctive subset-specific contributions to the WBIFNS. In a subsequent analysis, the effects of type I interferon on cellular blood composition in patients with SLE and hepatitis B were also studied over time. We found that type I interferon mediates significant alterations in whole blood composition, including a neutropenia and relative lymphocytosis. Given different effects of type 1 interferon on different leukocyte subsets, these shifts confound measurement of a type 1 interferon signature in whole blood. To minimize and overcome these limitations of the WBIFNS, we suggest to measure IFN-induced transcripts or proteins in a specific leukocyte subset to improve clinical impact of interferon biomarkers. Key messages: Myeloid cells contribute more to the WBIFNS in SLE than their lymphocytic counterpart.Very similar leukocyte subsets reveal distinctive IFN signatures.IFN alpha mixes up composition of blood and leads to a preferential neutropenia, yielding relative lymphocytosis.",
keywords = "Biomarker, Disease activity, Systemic lupus erythematosus, Type I interferon",
author = "Romy Strau{\ss} and Thomas Rose and Flint, {Shaun M.} and Jens Klotsche and Thomas H{\"a}upl and Markus Peck-Radosavljevic and Taketoshi Yoshida and Chieko Kyogoku and Alexandra Flechsig and Becker, {Amy M.} and Dao, {Kathryn H.} and Andreas Radbruch and Burmester, {Gerd R{\"u}diger} and Lyons, {Paul A.} and Davis, {Laurie S.} and Falk Hiepe and Andreas Gr{\"u}tzkau and Robert Biesen",
year = "2017",
month = "3",
day = "29",
doi = "10.1007/s00109-017-1515-7",
language = "English (US)",
pages = "1--13",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Type I interferon as a biomarker in autoimmunity and viral infection

T2 - a leukocyte subset-specific analysis unveils hidden diagnostic options

AU - Strauß, Romy

AU - Rose, Thomas

AU - Flint, Shaun M.

AU - Klotsche, Jens

AU - Häupl, Thomas

AU - Peck-Radosavljevic, Markus

AU - Yoshida, Taketoshi

AU - Kyogoku, Chieko

AU - Flechsig, Alexandra

AU - Becker, Amy M.

AU - Dao, Kathryn H.

AU - Radbruch, Andreas

AU - Burmester, Gerd Rüdiger

AU - Lyons, Paul A.

AU - Davis, Laurie S.

AU - Hiepe, Falk

AU - Grützkau, Andreas

AU - Biesen, Robert

PY - 2017/3/29

Y1 - 2017/3/29

N2 - Abstract: Interferon alpha and its surrogates, including IP-10 and SIGLEC1, paralleled changes of disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon signature (WBIFNS)—the current standard for type I IFN assessment in SLE—does not correlate with SLE disease activity in individual patients over time. The underlying causes for this apparent contradiction have not been convincingly demonstrated. Using a multicenter dataset of gene expression data from leukocyte subsets in SLE, we identify distinctive subset-specific contributions to the WBIFNS. In a subsequent analysis, the effects of type I interferon on cellular blood composition in patients with SLE and hepatitis B were also studied over time. We found that type I interferon mediates significant alterations in whole blood composition, including a neutropenia and relative lymphocytosis. Given different effects of type 1 interferon on different leukocyte subsets, these shifts confound measurement of a type 1 interferon signature in whole blood. To minimize and overcome these limitations of the WBIFNS, we suggest to measure IFN-induced transcripts or proteins in a specific leukocyte subset to improve clinical impact of interferon biomarkers. Key messages: Myeloid cells contribute more to the WBIFNS in SLE than their lymphocytic counterpart.Very similar leukocyte subsets reveal distinctive IFN signatures.IFN alpha mixes up composition of blood and leads to a preferential neutropenia, yielding relative lymphocytosis.

AB - Abstract: Interferon alpha and its surrogates, including IP-10 and SIGLEC1, paralleled changes of disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon signature (WBIFNS)—the current standard for type I IFN assessment in SLE—does not correlate with SLE disease activity in individual patients over time. The underlying causes for this apparent contradiction have not been convincingly demonstrated. Using a multicenter dataset of gene expression data from leukocyte subsets in SLE, we identify distinctive subset-specific contributions to the WBIFNS. In a subsequent analysis, the effects of type I interferon on cellular blood composition in patients with SLE and hepatitis B were also studied over time. We found that type I interferon mediates significant alterations in whole blood composition, including a neutropenia and relative lymphocytosis. Given different effects of type 1 interferon on different leukocyte subsets, these shifts confound measurement of a type 1 interferon signature in whole blood. To minimize and overcome these limitations of the WBIFNS, we suggest to measure IFN-induced transcripts or proteins in a specific leukocyte subset to improve clinical impact of interferon biomarkers. Key messages: Myeloid cells contribute more to the WBIFNS in SLE than their lymphocytic counterpart.Very similar leukocyte subsets reveal distinctive IFN signatures.IFN alpha mixes up composition of blood and leads to a preferential neutropenia, yielding relative lymphocytosis.

KW - Biomarker

KW - Disease activity

KW - Systemic lupus erythematosus

KW - Type I interferon

UR - http://www.scopus.com/inward/record.url?scp=85016428254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016428254&partnerID=8YFLogxK

U2 - 10.1007/s00109-017-1515-7

DO - 10.1007/s00109-017-1515-7

M3 - Article

C2 - 28357476

AN - SCOPUS:85016428254

SP - 1

EP - 13

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

ER -